Amery W K
Janssen Research Foundation, Beerse, Belgium.
Drug Des Deliv. 1989 May;4(3):197-203.
The present review discusses the available clinical information dealing with the treatment of migraine with calcium entry blocking agents. The data on prophylactic therapy are limited to 3 compounds, of which flunarizine is the most extensively studied and the only substance whose activity is well established. Clinical experience with these agents in the acute treatment of migraine attacks is still very limited.